2Durie B G M,Salmon S E.A clinical staging system for multiple myeloma.Cancer.1975.36:832—836.
3Wilkins B S, O'Brien C J. Techniques for obtaining differential cell counts from bone marrow lzephoine biopsy speciments. J Clin Pathol, 1988, 41:558-561.
4李守静，临床误诊误治，1992年，4卷，147页
5潘健涛，新医学，1988年，7卷，361页
6姚善谦，中华肿瘤杂志，1985年，3卷，207页
7李松明，中华血液学杂志，1984年，4卷，269页
8黄又彭，北京医学，1981年，5卷，313页
9武忠弼.病理学[M].北京:人民卫生出版社,1993.62
10Durie & Salmon. A clinical staging system for multiple myeloma:cor relation of measured myeloma cell mass with presenting clinical features. Response to treatment and survival[J]. Cancer 1975,36: 842-854.
3Kouroukis T C, Baldassarre F G, Haynes A E, e/ al, Borlezomib in multiple myeloma: systematic review and clinical considerations [J]. Curr Oncol , 2014, 21 (4) : e573-e603.
4Murray MY, Auger M J, Bowles K M. Overcoming bortezomib resistance in multiple myeloma [J] . Biochem Soc Trans, 2014,42(4) :804-808.
5Ding J H, Yuan L Y, Huang R B, et al, Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF[J]. Eur J Haematol, 2014,93(4) :329-339.
6Xiang S, Sun Z, He Q, et al. Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells [J] . M ed Oncol, 2010 ,27 (2) :379-387.
7Borthwick G M, Johnson AS, Partington M, et al, Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism[J] . FASEB J, 2006,20 (12) :2009-2016.
8Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib [J] . Oncology (Williston Park), 2004,18(14 Supplll) :14-21.
9Fischel J L, Formento P, Milano G. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor ( Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors [J]. Br J Cancer, 2005,92 ( 6) : 1063 -1068.
10Siegel R, Ma J, Zou Z, et al, Cancer statistics, 2014 [J]. CA Cancer J Clin, 2014,64(1) :9-29.
